Pharma News

LY-3885125 by Eli Lilly and Co for Dyslipidemia: Likelihood of Approval

Photo of MEEFRO MEEFRO Send an email December 7, 2023
0 124,534 Less than a minute

LY-3885125 is under clinical development by Eli Lilly and Co and currently in Phase I for Dyslipidemia.

Source link
#LY3885125 #Eli #Lilly #Dyslipidemia #Likelihood #Approval

Photo of MEEFRO MEEFRO Send an email December 7, 2023
0 124,534 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *